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Riboswitches are a class of regulatory structures located in the 5’ untranslated region of 
many bacterial mRNAs. Validating riboswitch-ligand interactions has historically been costly 
and low-throughput. Recently, graphene field-effect transistors (G-FETs) have emerged as 
effective biosensors in detecting interactions of such regulators with charged, high molecular 
weight analytes. However, a bottleneck still exists in detecting relatively neutral small 
molecules. The Bacillus subtilis guanine riboswitch (Xpt) within the xpt-pbuX operon contains a 
purine-responsive aptamer region with affinity for guanine, hypoxanthine, and other purine 
analogs. The G-FET sensor revealed successful detection of Xpt-hypoxanthine interactions at 
saturating concentrations. The specificity of Xpt was also demonstrated by a lack of signal 
detection when incubated with adenine. Therefore, such G-FET devices are effective in detecting 
aptamer binding to small, electrically-neutral molecules, which will allow for rapid screening of 
potential therapeutic ligands. Further, different electrical observations of n-doping upon aptamer 
functionalization and p-doping upon ligand binding reveal unique interactions at the graphene 
surface. Molecular dynamics simulations were carried out to interpret experimental results and to 
determine if another well characterized aptamer (FMN) is a suitable candidate for G-FET 
studies. Trajectory data from the Xpt aptamer domain complexed with hypoxanthine (PDBID: 
4FE5) and guanine (PDBID: 1Y27) showed significant differences in root mean square deviation 
(RMSD) and radius of gyration (Rg) from their respective non-binding mutants. These findings 
provide evidence that compaction of the RNA phosphodiester backbone is responsible for 
graphene detection. RMSD and Rg differences from FMN (PDBID: 3F4E) indicate that this 




biosensors can provide an avenue for the discovery of novel antibiotics for aptamer targets to 




Following Sir Alexander Fleming’s landmark discovery of penicillin in 1928, modern 
antibiotics have transformed the treatment of infectious disease (Martens and Demain, 2017). 
The 1940s-1970s ushered in a “golden era” of antibiotic discovery, as a wave of first-generation 
compounds targeting essential bacterial functions were discovered (Hutchings et al., 2019). 
Antibiotics have been used as the primary defense against bacteria, and are administered 
prophylactically to prevent infection in patients undergoing chemotherapy, surgery, or dealing 
with chronic disease (Monseratt-Martinez, 2019). This influx of novel antibiotics resulted in a 
shift in mortality from communicable to non-communicable diseases in the United States 
(Adedeji, 2016). The average life expectancy of US citizens rose from 54 years old in 1920 to 
nearly 80 years today (Shrestha, 2006).  
Despite such a dramatic improvement to human health, the emergence of antibiotic 
resistance has long posed a serious threat to existing therapeutics (Figure 1). Cases of bacterial 
resistance are driven by random mutations that can be passed down within and between species 
(Ventola, 2015). Inter-species exchange of genetic elements is accomplished by several methods 
of horizontal gene transfer. These include conjugation (transfer of plasmids), transduction 
(bacteriophage-mediated gene transfer), and transformation (DNA uptake). Antibiotics eliminate 




consequence of artificial natural selection. In fact, resistance to all antibiotics in clinical use has 
























Figure 1. A Timeline of Antibiotic Resistance. Image Credit: 
Ventola, 2015. Timeline depicting the emergence of resistance to the 




Rising antibiotic resistance can be attributed to a combination of overuse, misuse, and 
limited drug development. Epidemiological studies have shown that antibiotic overuse directly 
scales with emergence of novel resistant strains (Dadgostar, 2019). A study analyzing trends of 
antibiotic consumption from 2000-2015 found that the global use of antibiotics has increased 
65%, with developing countries converging with the consumption levels of high-income 
countries (Roberts and Zembower, 2020). Further, an analysis of national pharmaceutical sales 
data revealed that the United States consumed approximately 22.0 standard units (standard unit 
equaling one dose) per person in 2010 (Boeckel et al., 2014).  Beyond the clinic, antibiotics are 
widely used in livestock. Approximately 80% of U.S antibiotics are used prophylactically in 
animals. This results in transmission of antibiotic-resistant strains through the food supply. 
Antibiotics are also excreted from livestock in urine and feces, and are dispersed via run-off, 
fertilizer, etc. (Ventola, 2015). Sub-minimum inhibitory concentrations (MIC) can also result in 
de novo selection of mutants (Gullberg et al., 2011).  High antibiotic concentrations were 
typically seen as the major culprit for clinically relevant resistance. However, sub-inhibitory 
dosages allow bacteria to continue division and selects for resistant strains (Andersson and 
Hughes, 2014). Therefore, administration of sub-inhibitory dosages in the clinical setting can 
compound with low concentrations found in the environment, producing a perfect storm for 
antibiotic resistance (Figure 2). 
The response to this crisis has proved inadequate, as development of new antibiotics has 
significantly declined due to economic and regulatory factors. In the United states, 
pharmaceutical mergers have lowered diversity in research & development, which means there 
are fewer groups searching for antibiotics (Martens and Demain, 2017). Many pharmaceutical 




more profitable drugs. The development of a new antibiotic costs roughly $1.5 billion according 
to a 2017 estimate, whereas average annual revenue is only $46 million a year (Plackett, 2020). 
A drug used to treat neuromuscular disease, on the other hand, has a net present value of roughly 







A 2019 report showed that there are over 2.8 million antibiotic-resistant infections each 
year, and over 335 thousand deaths due to such infections (CDC, 2019). An interagency group 
Figure 2. The Ecology of antibiotics and antibiotic resistance. Image Credit: 
Andersson et al., 2014. This flowchart shows the interplay of industry, medicine, and 
agriculture in their contribution to antibiotic resistance. This allows selection and 




on antimicrobial resistance estimates that this number has the potential to increase to 10 million 
deaths per year if no action is taken (“No Time To Wait”, 2019). This number rivals the number 
of global deaths per year due to cancer (Plackett, 2020). Beyond increased medical 
complications and mortality rates, infections with antibiotic resistant bacteria dramatically 
increases healthcare costs. The Centers for Disease Control and Prevention (CDC) estimates that 
treatment for antimicrobial resistance adds approximately $1,400 to the average hospital bill 
(Dadgostar, 2019). Bacterial resistance to all classes of existing antibiotics have been found 
(Ventola, 2015), and the CDC has determined a variety of bacterial species that pose an 
immediate medical and financial threat to the U.S Healthcare system. These include 
Vancomycin-resistant Enterococci, Methicillin-resistant Staphylococcus aureus, and drug-
resistant Tuberculosis (CDC, 2019). 
Current antibiotics only target a narrow range of cellular processes. In fact, they 
collectively disrupt only four essential functions, which are the synthesis of DNA, RNA, protein, 
or the cell wall (Blount and Breaker, 2006; Fair and Tor, 2014). There are only twenty-five 
targets that account for these activities, and nearly half of all antibiotics target the cell wall (Fair 
and Tor, 2014). The combination of rising resistance and lack of drug development places 
impetus on the development of new classes of antibiotics that bind new targets. 
 
Riboswitches as Antibiotic Targets 
 
Many essential bacterial processes, including transport and biosynthesis, are regulated by 
a class of mRNA structures called riboswitches. These elements are generally located in the 5’ 
untranslated region of mRNAs and bind specific small molecules present in the cytosol (Baird et 
al., 2010). In response to binding of cognate ligands, riboswitches generally undergo 




genetic control via self-cleavage and trans hybridization to other target mRNAs (Loh et al., 
2009; Collins et al., 2007). Therefore, ligand analogs that bind these structures could prevent 
expression of essential gene products and eliminate pathogenic bacteria. 
Riboswitches consist of an aptamer and expression domain. The aptamer domain is a 
highly structured region that binds specific ligands. It is found primarily in the 5’-untranslated 
region of bacterial mRNAs. The expression platform is downstream and regulates gene 
expression via secondary structure changes. A switching sequence is common to both of these 
domains (Figure 3). Incorporation of the switching domain into the expression platform results in 
formation of an anti-terminator loop, allowing full transcription of the mRNA. If the aptamer 
region dominates, this can lead to formation of a Rho-independent terminator that aborts 
transcription. The switching sequence is also utilized at the translational level to display or 
occlude the Shine-Delgarno sequence. This purine-rich ribosome-binding site interacts with 16S 
ribosomal RNA in order to initiate translation. Ligand binding can therefore promote or inhibit 





















Riboswitches are categorized by family and class. Riboswitches of the same family are 
known to bind the same metabolite. Different riboswitch classes can be found within a given 
family. Each class is distinguished by unique sequence conservation in the ligand-binding pocket 
as well as similarities in secondary structure (Edwards and Batey, 2010). There are currently 28 
different classes of riboswitches that have been discovered and experimentally validated 
(Panchal and Brenk, 2021).  Riboswitch families widely distributed amongst bacterial species 
provide promising broad-spectrum antibiotic targets. Some riboswitches prevalent amongst 
pathogenic species include flavin mononucleotide, lysine, and S-adenosyl methionine-I (Penchal 
and Brenk, 2021). Those that are species-specific provide a means to eliminate pathogenic 
bacteria without harming the microbiome and reducing the risk of resistance. Narrowing 
bacterial targets is advantageous over broad-spectrum drugs because it puts evolutionary 
Figure 3. (A) Transcriptional Riboswitch Regulation. Image Credit: Batey et al., 2010. 
Diagram of the different domains of a riboswitch operating at the transcriptional level. 
Ligand binding (+M) incorporates the switching sequence into the expression platform to 
allow transcription. The unbound (-M) state results in an anti-terminator that inhibits 
transcription. (B) Translational Riboswitch Regulation. Image Credit: Breaker, 2018. 





pressure on a single species as opposed to multiple species. This eliminates horizontal gene 
transfer, and ultimately decreases the probability of increased bacterial fitness. These rare 
riboswitches can exhibit sequence and structural similarities to certain classes, but contain 
mutations that alter ligand specificity. For instance, FMN riboswitch variants that reject FMN 
ligands have been discovered exclusively in Clostridium difficile strains. More specifically, an 
FMN variant subtype 2 riboswitch binds riboflavin and certain FMN light-degradation products 
(Atilho et al., 2019).  
 Riboswitches are sought-after antibiotic targets for several reasons. First, riboswitches are 
found predominantly in prokaryotes and are absent in higher-order eukaryotes (Deigan and 
Ferré-D’ Amaré, 2011). Further, aptamer domains exhibit specific interactions with their cognate 
ligands. For instance, lysine and purine riboswitches form ligand-binding pockets that 
completely encapsulate their respective ligands, thus preventing binding of chemically similar 
compounds. This extreme specificity is exhibited in the ability of purine riboswitches to 
discriminate between guanine and adenine due to a single pyrimidine at position 74. A simple 
C74 to U74 mutation results in a change in affinity from guanine/hypoxanthine to adenine due to 
differential Watson-Crick base pairing (Gilbert et al., 2009). Such high specificity makes some 
riboswitches antibiotic targets that will not result in major composition changes to the gut 
microbiome. In fact, a computational study identified seven riboswitches as “potent drug 
targets.” Such riboswitches exhibited high prevalence in pathogenic gut bacteria and were 
observed in less than 20% of the genomes of benign gut bacteria (Kumari and Som, 2019).  
 Ribo-regulation has been implicated in the mechanism of several existing antibiotics 
whose toxicity had previously not been well understood. For example, pyrithiamine (PT) is a 




decades ago. More recently, it had been shown that phosphorylated PT controls expression of 
structural genes by binding the TPP riboswitch (Sudarsan et al., 2015). The mechanism of action 
of roseoflavin, an analog of FMN and riboflavin, has also been recently attributed to riboswitch 
binding. Roseoflavin binding to the FMN riboswitch has been experimentally validated by 
observing decreased expression of a reporter gene downstream of an FMN aptamer in B. subtilis 
(Deigan and Ferré-D’ Amaré, 2011). Therefore, such fortunately discovered analogs provide 
evidence that riboswitches can be used as therapeutic targets.  
 It is important to understand that riboswitches are not perfect drug targets. Mutations in 
the aptamer region can render ligand analogs ineffective. For example, PT-resistant bacteria 
derepress enzymes involved in thiamine and TPP biosynthesis because of a reduced affinity for 
thiamine analogs (Sudarsan et al., 2015). Another popular resistance mechanism involves 
expression of proteins that modify or remove the inoculated antibiotic. In fact, B. subtilis 
overexpressing a purine exporter is resistant to 2-fluoroadenine toxicity (Blount and Breaker, 
2006). Antimicrobial metabolites may also be responsible for off-target effects that can harm the 
host or even increase pathogenicity.  Even though there have been no riboswitch classes 
discovered in humans, there could be potential interactions with mammalian proteins.  
Pyrithiamine, for example, has been shown to induce thiamine deficiency by inhibiting enzymes 
responsible for conversion of dietary thiamine to thiamine pyrophosphate (Sudarsan et al., 2015). 
Such PT-induced deficiencies result in encephalopathy in mice with similar neurological 
symptoms to Wernicke’s encephalopathy in humans (Butterworth and Héroux, 1989). The 
riboflavin analog, roseoflavin, had previously been shown to inhibit growth in L. monocytogenes 
via inhibition of the gene imo1945 downstream of the FMN riboswitch. However, it 




the transcription factor prfA (Mansjö and Johansson, 2011). These drawbacks are fairly minor 
relative to the impact ncRNA targets will have on combatting antibiotic resistance. Further, it is 
possible to design riboswitch-targeting compounds that do not interact with host bacterial 
enzymes.  
Methods for Riboswitch Discovery 
 
 Discovery of riboswitches can be attributed to a combination of comparative genomics 
and high-throughput sequencing. Comparative genomics algorithms have uncovered many 
highly conserved ncRNA classes, but bottlenecks exist in the discovery of rare classes. Current 
methods of computational riboswitch discovery involve a variety of bioinformatic techniques. 
These methods can include a combination of machine learning, covariance models, and Hidden 
Markov Model (HMM) algorithms (Antunes et al., 2018). The signature characteristic of 
structure RNAs identified by many of these approaches is conserved sequences coupled with 
nucleotide covariation across species.  Nucleotide covariation is exhibited in structured RNAs 
when a mutation that disrupts secondary structure is rescued by another mutation that recovers 
the lost base pair. Covariation analysis in multi-sequence alignments have led to the discovery of 
many common ncRNAs, particularly riboswitches and ribozymes. When a conserved aptamer 
region is identified, potential ligands are predicted by analyzing the product of the downstream 
gene, but the process of identifying ligands from such guesses often results in years of trial and 
error (Meyer, 2009; Greenlee et al., 2018; Sherlock 2020). 
In order to identify rare riboswitch classes, various strategies have been employed to 
select subsets of intergenic regions that are known to be enriched with riboswitch motifs 
(Weinberg et al., 2017). However, many of the undiscovered rare riboswitches are clade specific, 




Sequencing techniques involving the bacterial transcriptome can uncover such riboswitches. 
Term-seq, a modified form of RNA-seq, can identify prematurely terminated transcripts that are 
characteristic of riboswitch transcriptional termination. This method circumvents the limitations 
of comparative sequencing due to its ability to identify divergent or recently evolved ribo-
regulators (Dar et al., 2016; Warrier et al. 2018). Although discovery of novel riboswitches can 
be achieved by computational and sequencing methods alone, experimentally validating 
interaction of aptamer regions with their binding cognates remains essential. 
Current Methods for Ligand Screening  
 The standard approaches for validating riboswitch-ligand interactions include in-line 
probing and Selective 2’-Hydroxyl Acylation analyzed by Primer Extension (SHAPE). These 
methods are costly and inherently low-throughput. Further, once these binding interactions are 
determined, subsequent determination of therapeutic ligand analogs for antibiotic development 
suffers from the same inefficiencies.  
 In-line probing experiments can be used to confirm ligand interactions by analyzing 
conformational changes that occur upon binding. Under mildly basic conditions, unpaired 
nucleotides within a single-stranded RNA are susceptible to phosphodiester cleavage. An 
internal transesterification reaction ensues in which the 2’-OH attacks the phosphate moiety, 
producing a 2’,3’-cyclic phosphate and a 5’-hydroxyl terminus (Figure 4A) (Mlynsky and Bussi, 
2017). This reaction only occurs when these two groups are co-axial in a trigonal bipyramidal 
molecular geometry. This transition state is only achievable for unpaired bases. Upon ligand 
binding, the RNA undergoes a conformational change, resulting in different regions of unpaired 
or flexible nucleotides, and therefore different cleavage sites. Differences in RNA fragmentation 




electrophoresis (Urea-PAGE). In-line probing assays are subject to many limitations. For 
example, it takes approximately 1-3 days for complete RNA fragmentation, and the PAGE gel is 
typically limited to about 30 samples. For proper screening of analogs, hundreds of molecules 
may be sampled at varying concentrations, taking weeks for any significant results. Furthermore, 
these gels are typically observed using 32P radiolabel. A method that avoids the need to work 
with radioactive material is therefore desirable.  
 SHAPE can also be used to analyze conformational change upon ligand binding. This 
method exploits the fact that 3’ phosphodiester oxyanions modulate the nucleophilicity of the 
ribose 2’-OH. Flexible nucleotide positions better facilitate a transition state where the 3’-
phosphodiester bond increases 2’ reactivity. An electrophile, such as N-methylisatoic anhydride 
(NMIA) results in an acylated adduct that effectively impedes cDNA synthesis by reverse 
transcriptase (Figure 4B) (Merino et al., 2005). Changes in local structure can then be 
determined at single nucleotide resolution following binding of small molecules. SHAPE is 
considered the preferred method for RNA structural analysis because it does not require 
radioactivity and now takes advantage of various high-throughput sequencing techniques 
(Mailler et al., 2019). However, in the context of validating small molecule binding, SHAPE has 
several limitations. For instance, structural information can be lost for approximately 15 
nucleotides at the 5’ end and for 40-60 nucleotides at the 3’ end (Steen et al., 2010). To put this 
into context, the aptamer region of the B. subtilis xpt-pbuX guanine riboswitch (Xpt) is 
approximately 67 base pairs. Further, SHAPE protocols are complicated, costly, and require 
many reagents. Thus, there is a need for a method capable of validating interactions of both 
native and therapeutic small molecules with putative riboswitch aptamers that is simple, cheap, 






















Graphene Field-Effect Transistors (G-FETs) as Biosensors 
 
 Recently, Graphene-Field Effect Transistors have emerged as promising biosensors for 
the detection of riboswitch-ligand binding. These devices are particularly attractive for 


















































Trigonal Bipyramidal Transition State
Figure 4. (A) RNA Hydrolysis Mechanism. Note the trigonal bipyramidal transition 
state is necessary for hydrolysis, and is formed for flexible nucleotides. (B) RNA 
SHAPE Mechanism. Reaction with NMIA produces an adduct on the 2’ oxygen that 






highly sensitive.  G-FETs can be applied to affinity sensing by recognizing biomolecule-ligand 
binding via changes in electrical conductivity of the graphene surface.  In order to understand the 
logic behind G-FET sensing, it is important to review the unique electronic properties of 
graphene.  
 Graphene is a single-atom sheet of sp2-hybridized carbons arranged in a honeycomb 
structure. Single-layer sheets were first isolated by a Manchester group led by Andre Geim in 
2004 by “peeling” with cellophane tape (Allen et al., 2010). However, single-layer graphene is 
now commercially produced using chemical vapor deposition (CVD) on transition metal 
substrates (Zhang et al., 2013). Graphene exhibits extraordinarily high carrier mobility due to its 
unique electronic structure. In fact, carrier mobilities have been observed to exceed silicon 
semiconductors by two orders of magnitude. Graphene also exhibits ambipolarity as a zero band 
gap semiconductor. This means that the voltage band and conductance band intersect at a single 
point called the Dirac point. The Fermi level passes through this point, and can be tuned by 
electrical or chemical doping.  Therefore, Graphene Field-Effect Transistors can change the 
proportion of carriers (holes or electrons) by an external electric field (via a “gate” voltage) 
applied through an ionic liquid or via a dielectric in a capacitive setup. Alternatively, the charge 
can be modified by attaching molecules that are either electron-rich (n-doping) or electron-
deficient (p-doping). In measuring resistance versus gate voltage, p-doped graphene exhibits a 
positive shift in the Dirac voltage (VD), whereas n-doped graphene exhibits a negative shift in 
VD. In this setup, the VD is observed as a maximum in resistance. Observed shifts in Dirac 
voltage can therefore be very useful in measuring binding events on the graphene surface 











 G-FET devices consist of a graphene channel placed between two electrodes (the source 
and the drain), with a third gate electrode controlling charge (Figure 7A). When a charged 
biomolecule such as an RNA aptamer binds to the graphene surface, the redistribution of 
extrinsic charge changes the electric field and thus the conductivity of graphene (Figure 5A) 
(Tsai and Willner). This results in a shift in Dirac Voltage as mentioned above (Figure 6). When 
a ligand binds the aptamer, the resulting changes in tertiary structure further modifies the 
distribution of extrinsic charge, resulting in further shift of VD (Figure 5B, Figure 6).  
 In order to immobilize RNA aptamers onto the graphene surface, a linker molecule must 
be attached by either covalent or non-covalent bonding. There are various methods of covalent 
functionalization, including halogenation, hydroxylation, azidation, etc. However, covalent 
bonding of linkers changes the sp2 hybridization of the carbon lattice. In order to avoid 
Figure 6. Resistance vs. Gate Voltage (Vg).  Image 
Credit: Kumar et al., 2020. Typical readout on G-FET 
device. Change in resistance vs. gate voltage for the 
device as fabricated (control), after addition of PBASE 
linker (red), after aptamer attachment (blue), and upon 
exposure to Human Carbonic Anhydrase 1 (CA1) ligand 






Figure 5. (A) Schematic and (B) crystal 
structure of indicating compaction of RNA 
around a bound ligand. Image Credit: 
Meyer, 2020. When a ligand binds its aptamer 
target, conformational changes of bound RNA 
will increase its proximity to the graphene. 
The resulting increased charge from either the 
ligand or compacted RNA induces a shift in 






disrupting graphene’s conductivity, one can take advantage of non-covalent interactions between 
the graphene surface and polyaromatic hydrocarbons. For instance, pyrenebutyric acid N-
hydroxysuccinimide ester (PBASE) is a commonly used linker because the pyrene group is 
attracted to the graphene surface by π-π stacking. Also, the ester is an excellent electrophile that 
can facilitate addition of amine-labeled biomolecules (Figure 7B, C). Non-covalent interactions 
reduce alterations to the graphene surface, and minimize perturbations of its electronic properties 
(Forsyth et al., 2017).  
Even though G-FETs have been praised for their remarkable sensitivities and biosensor 
applications, the introduction of ionic solutions puts constraints on detection limits. Ionic 
solutions become necessary to mimic biological environments and protect biomolecules. For 
instance, RNA in pure aqueous solution is more prone to self-cleavage as opposed to PBS, and 
Mg2+ plays important roles in tertiary structure formation. Buffers of high ionic strength 
introduce Debye screening in which the effective charge of immobilized biomolecules or 
analytes is decreased. The Debye length is the distance from the graphene surface outside of 
which extrinsic charges cannot be detected. Debye length is inversely proportional to the 
concentration of ionic solvent, with 1x PBS producing measurable charges within 0.7 nm, 0.1x 

















































1-Pyrenebutyric acid N-hydroxysuccinimide ester
(PBASE)
PBASE-linked aptamer
Figure 7. (A) Diagram of a typical G-FET. Image Credit: Kumar et al., 2020. (B) 1-
Pyrenebutyric acid N-hydroxysuccinimide ester linker. (C) PBASE covalently bound 




Figure 8. Visual representation of the effect of buffer concentration on the 

















Molecular Dynamics Simulations  
 
 Molecular dynamics (MD) simulations have gained popularity among molecular 
biologists in recent years and have important applications in approximating structural changes in 
macromolecules. MD simulations were first carried out for simple gasses by Alder and 
Wainright in the 1950s. In the 1970s, MD simulations were extended to simulation of a protein, 
providing the foundation for modern computational techniques (Meller, 2001). With the advent 
of more powerful hardware, biological systems can be modelled over biologically relevant 
timescales (i.e., nanoseconds). Computational tools such as MD are used with a variety of 
experimental techniques, such as crystallography and Förster resonance energy transfer (FRET) 
to help interpret or predict experimental results (Hollingsworth and Dror, 2018) 
Using Newton’s laws of motion, MD simulations can predict the movement of every 
atom in a system as a function of time (Hollingsworth and Dror, 2018). The result is a trajectory 
of all the particles in the system defined by both position and velocity vectors. Molecular 
dynamics utilizes force fields that are described by classical mechanics thanks to the Born-
Oppenheimer approximation.  This allows simulations to ignore quantum mechanical 
contributions of electrons, and focus on the dynamics of the nuclei (Meller, 2001; Hollingsworth 
and Dror, 2018).  
In order to increase the accuracy of biological MD, aqueous solvents must be modelled 
and incorporated into the system. However, limited processing power puts limits on the amount 
of solvent molecules, and placing the solute in a box of solvent is not sufficient. One way around 
this problem is based on periodic boundary conditions (Meller, 2001). By using this approach, 




image. This prevents solvent molecules at the box’s edge from boiling off into space (Walker, 
2015).  
Molecular dynamics can be used to investigate a wide range of biomolecules, including 
nucleic acids. In the case of riboswitches, MD simulations can be used to probe the 
conformational changes that result from the addition and removal of a ligand. This requires 
performing MD simulations on a starting crystal structure of an aptamer bound to its ligand and 
comparing it to a simulation of the unbound form (Šponer et al., 2014).  
In order to analyze the resulting differences in conformation between an unbound (apo) 
and bound (holo) structure, it is useful to calculate the root mean square deviation (RMSD) and 
the radius of gyration (Rg). The RMSD measures the average distance between a group of atoms 
of two superimposed structures. This distance can be calculated for any atom type or group (i.e., 










where n is the number of groups of equivalent atoms and di is the distance between the atoms in 
the i-th group (Kufareva and Abagyan, 2012). RMSD can also measure the average distance 
between atoms at time t and atoms at time zero (starting structure), as is the case of the 
experimental design in this paper. Despite having such practical use in determining changes in 
conformation, RMSD is subject to some limitations. For example, local changes in structure can 
be masked by these measurements. This means that a fairly rigid macromolecule with some 




flexibility (Sargsyan et al., 2017). Therefore, it becomes wise to perform radius of gyration as 
another set of structural measurement. Radius of gyration is a measure of the compactness of a 





where mi is the mass of the molecule and ri is the distance from the center of mass (Lobanov et 
al., 2008). A larger distance from the center of mass indicates a lower degree of compaction. 




In the current study, two riboswitch aptamer domains were investigated: Xpt (Figure 9A, 
B) and FMN (Figure 10A, B). Both aptamers are well characterized with known ligands and a 
wealth of data surrounding their interactions. The B. subtilis guanine (Xpt) aptamer was used for 
both in vitro G-FET studies and MD simulations. This aptamer domain is part of a riboswitch 
that controls expression of the xpt-pbuX operon. This two-gene operon encodes xanthine 
phosphoribosyltransferase and xanthine permease, which are enzymes of the bacterial purine 
salvage pathway. It is tightly regulated by guanine binding in vivo, and also shows high affinity 
for hypoxanthine. However, it is not specific for adenine (Batey et al., 2004). The Fusobacterium 
nucleatum FMN aptamer region was exclusively used for MD. This riboswitch controls 
expression of genes involved in the biosynthesis and transport of riboflavin (Serganov et al., 
2009). Riboflavin (vitamin B2) serves as an important organic cofactor in many cellular redox 
reactions (Cisternas et al., 2018).  Therefore, ligand binding to these two aptamers negatively 




Previous studies have shown noticeable shifts in Dirac voltage when aptamers bind large, 
charged molecules such as proteins (Kumar et al., 2020). However, it is still unclear as to 
whether G-FET devices are capable of detecting binding of small, relatively neutral molecules. 
This study intends to determine the capability of G-FET devices in sensing binding events 
between RNA aptamers and such molecules. Investigators in the Meyer and Burch labs have 
hypothesized that compaction of aptamer regions around these small molecules will increase 
extrinsic charge closer to the graphene surface, and therefore cause a shift in VD. To test this 
hypothesis, the aptamer domain of the Xpt guanine riboswitch was attached to the graphene 
surface.  
In order to accomplish this, it was necessary to develop a cost-effective method to attach 
PBASE linkers to the aptamer 3’ end. This was accomplished by amine labeling the 3’ end with 
ethylenediamine and subsequent nucleophilic acyl substitution. G-FET studies were carried out 
after confirming successful attachment of aptamers to graphene by atomic force microscopy 
(AFM). Preliminary results showed a large, positive VD shift after addition of 500 nM 
hypoxanthine and no significant change after addition of a non-binding purine, adenine.  
In order to provide further evidence that this positive signal change was due to aptamer 
conformational changes, molecular dynamics studies were performed. RMSD and Rg differences 
were analyzed by comparing the dynamics of Xpt to a single pyrimidine mutant at position 74. 
As stated previously, a C74U point mutation drastically changes Xpt binding affinity from 
guanine/hypoxanthine to adenine. Analysis of RMSD and Rg differences revealed a striking 
conformational change in 4FE5, and to a lesser extent in 1Y27. These in silico findings add 
further evidence that G-FET signal changes are caused by conformational changes of aptamer 




future aptamer candidates. Therefore, trajectory data for the F. nucleatum FMN riboswitch was 
compared to Xpt. The FMN aptamer structure did not outperform Xpt mutants in RMSD or Rg, 
and therefore may not cause any significant G-FET signal change upon incubation with FMN.  
Our findings suggest that G-FET sensors are capable of sensing aptamer-ligand 
interactions. Such a device will dramatically increase the rate at which these interactions can be 
confirmed, and will also provide rapid screening of putative antibiotics. This will not only aid in 
our current understanding of bacterial riboswitches, but will also serve as a key innovation in 











 Figure 9. (A) Crystal structure of Xpt complexed with 
hypoxanthine (4FE5). (B) Chemical structures of ligands involved 
with Xpt. Both hypoxanthine and guanine bind with high affinity to the 


























Materials and Methods 
Bacillus subtilis Chromosomal Extraction 
 
 Cells were grown to stationary phase at 37ºC overnight in 2.0 mL volumes. After 
incubation, 1.5 mL of cells were harvested by centrifugation at 4ºC and 14,500 rpm on a Tomy 
centrifuge. The cell pellet was resuspended in 360 µL saline-EDTA. Another round of 
centrifugation (3 min) followed with resuspension in 360 µL saline-EDTA. Cells were freeze-
thawed in 3 cycles of cooling at -80ºC. Then, 40 µL lysozyme was added and the sample was 
incubated at 37ºC for 35 minutes. Forty µL of 1% Sarkosyl detergent and 20 µL of Proteinase K 
were added to disrupt plasma membranes and degrade proteins/nucleases, respectively. Phenol, a 
protein remover, was added at 400 µL. The sample was mixed well and centrifuged at max speed 
at 4ºC. The aqueous layer was pipetted into a new tube, to which 400 µL phenol:chloroform 















Figure 10. (A) Crystal structure of Flavin Mononucleotide (FMN)-specific 





400 µL chloroform was added and the above steps were repeated. The purified aqueous layer 
was then ready for PCR amplification. 
Transcribing the Xpt Aptamer 
 
5’ggaTCATATAATCGCGTGGATATGGCACGCAAGTTTCTACCGGGCACCGTAA
ATGTCCGACTATGGTc3’oligonucleotides were PCR amplified with primers containing a T7 
phage promoter overhang.  Successful amplification was confirmed by running PCR products on 
an agarose gel at 135 V and visualizing bands relative to a 100 base pair marker. Following 
characterization, the resulting DNA was purified using a Zymo DNA minikit and subjected to in 
vitro transcription with T7 RNA polymerase. Samples ran at 35 mA on a denaturing urea PAGE 
gel for approximately two hours before extraction. Bands were visualized by briefly exposing the 
gel to UV radiation (~254 nm) and cut out into Eppendorf Tubes. The fragments were rocked for 
around thirty minutes in a Crush Soak Buffer, and the eluted aptamers were transferred to a new 
tube to which 10% 3M sodium acetate, 1 μL glycogen, and two volumes of ethanol were added. 
After storage at -20ºC for at least one hour, the precipitate was spun down and the supernatant 
removed. The pellet was resuspended in deionized water and a sample placed in a NanoDrop 
UV-Vis Spectrophotometer to determine the final concentration. 
	 Developing an Effective 3’-labeling Protocol 
 
 Amine labeling of the 3’ end was modified from Proudnikov et al. A maximum of 1 nmol 
RNA in 5 μL water was mixed with 1 μL freshly prepared NaIO4. The resulting mixture was 
incubated for 20 minutes at room temperature to allow oxidation to occur. RNA was then 
precipitated with 2% LiClO4 in acetone followed by two more washes with acetone. NaIO4-
oxidized RNA was further dissolved in 10 μL of 50 mM sodium acetate buffer at a pH of 4.0. 




Three μL of this reagent was added, and the solution was incubated at 37ºC for 1 hour. Reductive 
amination was carried out by adding 1.5 μL of 200 mM NaCNBH3 catalyst in dry acetonitrile. 
Reduction lasted 30 minutes before precipitation with 2% LiClO4 in acetone and drying.  
Amine-labeled RNA was then dissolved in 200 μL NaB buffer at pH 8.5. The PBASE 
linker was dissolved DMSO to make a concentration of approximately 14 mM, and 50 μL was 
added to the reaction mixture. The nucleophilic acyl substitution reaction was carried out for 2 
hours on a rocker at room temperature. The PBASE-RNA conjugate was finally precipitated 
using a 9:1 V/V ethanol/sodium acetate mixture. RNA concentrations were determined using 
spectrophotometry and, more recently, a quantitative gel densitometry standard curve. When gel 
densitometry was employed, PBASE-labeled RNA was loaded in a Urea-PAGE gel to separate 
excess PBASE linker. The densitometry gel was stained with SYBR Green II fluorophore for 
around 20 minutes and illuminated with 300 nm UV transillumination.  A calibration plot of 
fluorescence vs. concentration was constructed to calculate the concentration of the unknown.  
Atomic Force Microscopy Measurements 
 
Patterned graphene was initially submerged in 1x PBS (pH 7.4) for 5 minutes. It was then 
transferred to another well to which 1 μM PBASE-labeled RNA dissolved in 0.1x PBS was 
added. After incubation for 2 hours, graphene was rinsed with 0.1x PBS and deionized water to 
remove any unlinked aptamer.  The sample was then dried with nitrogen, and placed in an inert 
argon atmosphere for AFM imaging. The ezAFM (NanoMagnetics Instruments) operated in non-
contact mode to scan the surface for a graphene-silicon oxide edge. Once an edge was identified, 
the cantilever auto-landed and the area was scanned. Several measurements of graphene 







 All G-FET devices were developed by the Boston College Burch lab (Kumar et al., 
2020). G-FETs were functionalized with aptamers by incubating with 1 μM PBASE-RNA in 1x 
PBS for 2 hours. G-FET resistance was then measured with a digital multimeter by sweeping a 
liquid gate voltage from 0 to 1.7 V. A saturating concentration (500 nM) of ligand in 0.1x PBS 
was added to the functionalized G-FET, and measurements were taken after 30 minutes. 
Measurements were performed in 0.1x PBS to reduce Debye screening effects and increase 
signal. The change in maximum resistance (Dirac Point) of the resistance versus gate voltage 
plot was measured to determine ligand binding. A platinum wire 0.5 mm in diameter was used 
for liquid gating. 




 The initial hypoxanthine, guanine, and FMN riboswitch structures were obtained from 
Protein Data Bank crystal structures. Apo structures were created by stripping off the respective 
ligand and creating topology and coordinate files with tLEaP. The structure was solvated with 
the TIP3PBOX water model in a periodic box with 10 angstroms of padding (Barton and 
Luchko, n.d.). Sodium counterions were added to neutralize the system. For the bound system, 
Antechamber was used to create parameters for the respective ligands. Hydrogens were added to 
the ligand crystal structures using the Amber “reduce” program. The Generalized Amber Force 
Field (GAFF2) was used to generate inputs for the ligand (Case et al., 2020). Topology and 
coordinate files for the ligand-bound structure were also generated using tLEaP. Both apo and 




with a 10 Å margin (Case et al., 2020). Sodium counterions were again added to achieve charge 
neutrality.  
Creating an in-silico Mutant Aptamer 
 
 The wildtype aptamers of hypoxanthine-bound and guanine-bound Xpt were taken from 
the PDB crystal structures (PDBID: 4FE5 and 1Y27, respectively). The C74U mutant aptamer 
was then generated by loading the structure into Pymol and using the Mutagenesis Wizard. 
Molecular Dynamics Simulation Protocols 
 
 MD simulations were performed using Amber20. All systems were equilibrated using a 
nine step protocol modified from the Rizzo Lab website at Stony Brook University (Chachra and 
Rizzo, 2008). Steps 1 and 2 involved a 5000 cycle minimization and subsequent 50 ps 
equilibration using 5.0 kcal/mol*Å2 heavy atom restraints at 298 K. Minimization continued over 
the next three steps at 1000 cycles (3, 4, 5) using heavy atom restraint weights of 2.0, 0.1, and 
0.05 kcal/mol*Å2, respectively. Two equilibration rounds at 50 ps and 298.15 K (6, 7) followed 
using restraint weights of 1.0 and 0.5 kcal/mol*Å2.  Steps 8 and 9 restrained RNA backbone 
atoms (P, OP1, OP2, O5’, C3’, C4’, C5’, O3’) using 1.0 and 0.1 kcal/mol*Å2, respectively. A 40 
ns MD simulation was then carried out. All steps calculated non-bonded interactions using an 8 
Å cutoff.  All MD protocol input files for the 1Y27 complex can be seen in the Supplementary 
Materials section.   
Trajectory Analysis 
 
 All trajectories were analyzed using CPPTRAJ. Root mean square deviation (RMSD) 
values were calculated for backbone atoms only. Radius of gyration and residue distances were 
used for further analysis. Water molecules and sodium counterions were stripped and systems 






 The Visual Molecular Dynamics (VMD) program was used to visualize trajectory files 
produced by MD production runs. Molecules were created by loading topology files with their 
corresponding trajectories. Both the apo and bound systems were loaded into the visualizer tool.  
The RMSD trajectory tool was used to align the two systems in space, and the trajectory movie 
was generated using the “Movie Maker” extension. 
Results 
 
Modifying a 3’ Labeling Protocol 
 
In order to allow for strong binding of RNA to the graphene surface, PBASE was 
conjugated to the 3’ end of the RNA.  The pyrene group is noncovalently attracted to the 
graphene surface by π-π overlap, allowing formation of a homogenous monolayer. The NHS 
ester allows for easy attachment of 3’ amine-labeled aptamers following nucleophilic acyl 
substitution (Tsang et al., 2019). There are two common methods for 3’-amination of RNA: 
modification using Poly(A) polymerase or T4 RNA ligase in combination with a modified 
nucleotide that includes 3’ amination. However, T4 RNA ligase tailing reactions are inefficient 
and require high concentrations of pCp and enzyme. Poly(A) polymerase is also fairly inefficient 
for short RNAs (Huang and Szostak, 1996).  Therefore, a decision was made to pivot to a 
chemical modification that is simple, efficient, and inexpensive. This is accomplished first by 
oxidation of the 3’-cis-glycol and further reductive amination using sodium cyanoborohydride 
catalyst (Figure 11).  
Reductive amination protocols were modified from a fluorescent labeling scheme 
(Proudnikov and Mirzabekov, 1996). A maximum of 1 nmol NaIO4-oxidized RNA can be used 




RNA, only a fraction of the maximum molar amount was oxidized per reaction. Therefore, 
multiple oxidized RNA precipitates were combined up to 1 nmol before dissolving in sodium 
acetate. Increasing the molar concentration of oxidized RNA prior to reductive amination 
significantly reduced the time required for labeling.   
Once amine-labeled RNA was precipitated, the PBASE linker was attached (Figure 11). 
A saturating amount of PBASE (14 mM) was used. Initially, the concentration of labeled RNA 
was roughly estimated using a spectrophotometer. However, more robust purification steps 
proved necessary for more accurate quantitative analysis because excess linker interfered with 
absorbance values. Therefore, PBASE-labeled RNA was loaded in a Urea-PAGE gel to separate 
excess linker. Concentration was determined via electrophoresis and quantitative gel 
densitometry. A calibration plot of band density (raw volume) vs. concentration was constructed 
to calculate the concentration of the unknown (Figure 12).  Although the concentration of labeled 
RNA may be able to be estimated via spectrophotometry, the presence of a conjugated pyrene 
group on PBASE interferes with the characteristic absorbance of RNA at 260 nm (Maeda et al., 
2001). Therefore, densitometry seems to be a longer, but more accurate method to confirm 
concentration. Also, even though an additional purification step results in lower yields of labeled 
RNA, it is a necessary step to create a homogenous monolayer of PBASE-linked aptamer on the 
graphene surface. Uniform distribution of aptamer is necessary to maximize sensitivity. If 
unconjugated PBASE linker surrounds each PBASE-RNA conjugate on the graphene surface, it 


















Figure 11. 3’ labeling scheme for ethylenediamine and PBASE attachment. The 
exact mechanism is unknown and potential intermediates are mentioned in the discussion 
section. 
A 
Figure 12. Gel Densitometry Standard Curve. Example of a standard curve 
used to determine unknown labeled-RNA concentration. Raw volume represents 























































Atomic Force Microscopy Confirms Binding of PBASE-labeled Aptamers 
 
Functionalization of the graphene surface with PBASE-labeled Xpt probe was confirmed 
by atomic force microscopy (AFM). Measurements of the height difference between a graphene-
silicon oxide edge after immobilization of Xpt were quantified using an ezAFM. Figure 13 
shows a 5-6 nm height difference between the graphene and silicon-oxide substrate.  The 
theoretical thickness of graphene is approximately 0.34 nm (Tian et al., 2020) and the predicted 
height from the Xpt 3’ end is 6.52 nm. Therefore, it can be concluded that labeled aptamer was 
successfully immobilized to the graphene surface following a washing step (Figure 14). Since the 
AFM height measurement was lower than the predicted height, it is reasonable to assume that a 
portion of the unbound RNA had adsorbed onto the graphene surface. Single-stranded nucleic 
acids are known to adsorb to graphene surfaces due to van der Waals π-stacking interactions 
















Figure 13. Non-contact AFM to verify Xpt immobilization.  (A) Image of a 
graphene-silicon oxide edge of patterned graphene using ezAFM atomic force 
microscopy. Left half of the scan is silicon oxide whereas the right side is 
graphene with attached aptamers. (B) Plot showing difference in height between 
silicon oxide and labeled graphene (roughly 5-6 nm). Readings validate presence 
of PBASE-labeled Xpt on graphene surface. (C) Pymol image of Xpt aptamer 







Detection of Ligand Binding using Graphene Field-Effect Transistors 
 
We hypothesize that ligand binding to the Xpt RNA induces conformational changes in 
the RNA that change the charge density in graphene such that they can be detected through a 
change in G-FET Dirac point. To test this hypothesis, we assessed the G-FET resistance 
maximum under several conditions. The binding dissociation constant of the Xpt aptamer and 
hypoxanthine ligand in high magnesium ion concentrations is 50 nM (Batey et al., 2004). Based 
on this value, a saturating amount of hypoxanthine (500 nM) was used for the assays. After 
incubation of hypoxanthine with aptamer, there is a large positive shift in the G-FET resistance 
maximum (Figure 14A, E). Incubation with the target ligand therefore induced a conformational 
change in the aptamer that was detected by the biosensor. We also assessed the impact of a non-
interacting compound, adenine. Previous studies have shown that a single pyrimidine at position 
74 (Y74) discriminates between guanine/hypoxanthine and adenine by approximately 10,000-
fold (Gilbert et al., 2009). Figure 14B demonstrates that no shift is observed upon incubation 
with adenine. Therefore, the Xpt aptamer shows high specificity since the non-binding cognate 
did not induce any shift in the resistance maximum.  
An observed left shift in the resistance maximum after addition of Xpt alone (Figure 14C) 
has also been observed in recent literature (Tian et al., 2020). The doping effects of nucleic acids 
on graphene are highly dependent on the level of adsorption of these molecules and Debye 
screening. This is why both positive and negative shifts in Dirac voltage have been observed 
after binding of RNA to graphene (Tian et al., 2020, Kumar et al., 2020). Since the shift in Dirac 
voltage is proportional to the number of aptamers, ∆VD should increase with time as more 
aptamers attach to the surface. This was observed in Figure 15C as the left shift of VD increased 




Electrostatic gating theory places limits on conductance-based graphene sensors in 
detecting small, relatively nonpolar analytes (Wang et al., 2015; Tian et al., 2020). In order to 
demonstrate the inability of small, neutral molecules to cause detectable G-FET signal changes, 
500 nM hypoxanthine was added without aptamer (Figure 14D).  No observed signal changes 














































Xpt + 500 nM Hyp





























Xpt + 500 nM Ade

























Incubation with 500 nM Hypoxanthine


















































Molecular Dynamics Simulations 
 
 The large positive shift in Dirac voltage upon interaction of Xpt and hypoxanthine  
indicates an aptamer-induced increase in hole carrier concentration. Since it was proposed that a 
conformational change brought a large portion of the RNA backbone closer to the graphene 
surface, we decided to confirm this structural change using molecular dynamics. Molecular 
dynamics simulations are extremely useful in predicting conformational changes of a biological 
system upon addition and removal of ligands from a starting crystal structure. Two quantitative 
measurements of aptamer conformational change were calculated: root mean square deviation 
(RMSD) and radius of gyration (Rg). RMSD in this context was used to determine the distance 
between RNA backbone atoms of an initial structure and the structure at discrete timepoints 
(Figure 15A-E).  Radius of gyration was calculated to assess the degree to which these aptamer 
domains compact with respect to time (Figure 15F-J). The time-averaged RMSD and Rg 
calculations can be seen in Table 1. Also, we calculated the absolute value of the average 
difference in RMSD and Rg between apo and bound structures for all systems by paired student’s 
Figure 14. Plots of resistance vs. gate voltage on G-FET devices under various conditions. (A) 
A large (320 mV) shift after incubation with hypoxanthine reveals noticeable change in resistance 
maximum after addition of target ligand. (B) No shift upon incubation with 500 nM adenine show 
high specificity of Xpt for its target ligands. (C) Left shift over time observed with Xpt alone. (D) 
No observed shift upon incubation with hypoxanthine alone. Controls show high specificity of the 
Xpt aptamer for its target ligands as well as the inability of small, neutral molecules to cause 




















t-tests (Figure 16A, B).  The larger the difference in RMSD and Rg, the larger the conformational 
change following ligand addition. Means were calculated excluding the first 5 ns to allow 
systems to equilibrate and to eliminate outliers.  
 In order to determine the impact of hypoxanthine and guanine on Xpt folding, the 4FE5 
and 1Y27 crystal structures were utilized. We also created mutants of both structures (C74U) to 
change affinity from hypoxanthine and guanine to adenine. Since these mutants do not interact 
with their respective ligands, we suspected that addition of ligands into the binding pocket would 
induce limited conformational changes. It should also be noted that one should be cautious in 
comparing wildtypes and mutants of different crystal structures (i.e., comparing 4FE5 wt, mutant 
to 1Y27 wt, mutant). Differences in starting atomic positions between the crystal structures may 
impact resulting MD trajectories. Wildtype 4FE5 saw a significant difference in RMSD 
following ligand addition, indicating a conformational change (Figure 15A). Further, the 
wildtype complex exhibited a significantly lower Rg, meaning it became more compacted 
relative to its apo structure (Figure 15F). This provides evidence that introduction of 
hypoxanthine likely induced a conformational change that moved Xpt’s negatively charged 
sugar-phosphate backbone closer to the graphene surface, increasing hole-carrier density and 
allowing for a p-doping effect. This was indicated by a positive shift in VD in the G-FET 
experiments. This conformational change between apo and bound states can be visualized in the 
Supplementary Materials. The mutant 4FE5 apo and bound structures revealed a much less 
significant RMSD difference and Rg decrease upon addition of hypoxanthine (Figure 15B, G; 
Figure 16A, B). This decrease in conformational change and level of compaction proved that 
non-cognate ligands do not induce a significant change in tertiary structure. No observable VD 




 Since guanine is the typical binding cognate in vivo, it was necessary to assess the impact 
of this ligand on Xpt structural changes. We again saw a significant change in RMSD between 
apo and bound structures (Figure 15C). Rg also decreased in the bound state (Figure 15H). In 
comparing to 1Y27 C74U, the differences in wildtype were also significantly larger (Figure 16A, 
B). However, these differences were less pronounced compared to 4FE5 wildtype. This may 
imply that guanine will induce a smaller shift in VD compared to hypoxanthine. However, this 
difference may also be attributed to different crystal structures. In fact, 1Y27 wildtype and 4FE5 
mutant Rg measurements were extremely close (Table 2). Such results reinforce that comparison 
between crystal structures probably has limited predictive value. Regardless, both 4FE5 and 
1Y27 exhibited significant RMSD and Rg differences compared to mutant controls.  
The F. nucleatum FMN riboswitch (PDBID: 3F4E) was also subjected to MD 
simulations to determine if it will be a good candidate for G-FET experiments. This aptamer 
exhibited no significant change in either RMSD or Rg measurements. The FMN RMSD (Rg) 
difference between apo and bound states was approximately 0.16 Å (0.052 Å) (Table 2). These 
conformational changes are miniscule, and the G-FET may not be sensitive enough to detect 














































































































    Apo         Ligand  
Aptamer RMSD Rg RMSD Rg 
4FE5 10.6 (0.7) 
24.49 
(0.35) 3.0 (0.4) 
19.78 
(0.33) 
4FE5 C74U 4.4 (0.6) 
20.55 
(0.29) 3.1 (0.9) 19.9 (0.7) 
1Y27 3.42 (1) 20.7 (0.6) 2.20 (0.37) 
20.05 
(0.32) 
1Y27 C74U 2.50 (0.4) 
20.09 
(0.31) 2.8 (0.7) 20.1 (0.5) 
FMN 3.40 (0.38) 
22.97 
(0.21) 3.2 (0.5) 
22.92 
(0.19) 
Figure 15. (A-E) RMSD measurements over 40 ns for ligand-bound (complex) and unbound 
(apo) aptamers. (F-J) Rg measurements over the same time frame between complex and apo 
structures. 
Table 1. Average RMSD and Rg measurements after the first 5 ns. Averages were 
calculated in this way in order to allow systems to equilibrate. Parentheses indicate RMSD and 




































Condition Average RMSD Difference 95% confidence interval 
4FE5 7.59 [7.57, 7.61] 
4FE5 C74U 1.3 [1.27, 1.33] 
1Y27 1.23 [1.20, 1.25] 
1Y27 C74U 0.29 [0.27, 0.31] 
FMN 0.16 [0.14, 0.17] 
Condition Average Rg Difference 95% confidence interval 
4FE5 4.72 [4.71, 4.73] 
4FE5 C74U 0.68 [0.66, 0.69] 
1Y27 0.68 [0.67, 0.69] 
1Y27 C74U 0.023 [0.009, 0.037] 
FMN 0.052 [0.045, 0.058] 
Figure 16. (A) Average RMSD differences between simulated systems. *** p < 0.001 for all 
sample comparisons (ANOVA). (B) Average Rg differences between simulated systems. *** p 
< 0.001 for all sample comparisons (ANOVA).  







G-FET studies involving nucleic acids generally involve the purchase of amine-labeled 
aptamers. Also, PBASE linkers are typically added to the graphene surface first, followed by 
addition of amine-labeled RNA. Since it is our hope to scale up this device to allow for a large 
array of wells containing graphene devices, it is not cost effective to purchase large quantities of 
amine-labelled RNA. Therefore, we devised a low-cost alternative that involves 3’ amination 
followed by attachment of PBASE linker. Therefore, RNA aptamers will be attached to PBASE 
before introducing the sample to the graphene surface.  
The threat of antibiotic resistant bacteria has loomed since the conception of antibiotics. 
Unfortunately, barriers in research and lack of economic incentive have put serious limitations 
on the scope of our current anti-microbial arsenal. Current methods only target a narrow range of 
bacterial processes (Blount and Breaker, 2006; Fair and Tor, 2014), and cases of resistant strains 
to all clinically used drugs have been documented (Ventola, 2015). Therefore, in an effort to 
increase antibiotic diversity, discovery of novel therapeutic targets is paramount. Riboswitches 
are promising drug targets due to their high specificity for small molecules and concomitant 
regulation of essential microbe functions (Gilbert et al., 2009; Penchal and Brenk, 2021). 
Combinations of comparative genomics and sequencing techniques are used for discovery of 
putative riboswitches (Antunes et al., 2018; Warrier et al., 2018). However, subsequent 
identification of biological and therapeutic ligands is subject to trial and error, and confirmation 
of binding to their aptamer target is further limited by low-throughput assays (Meyer, 2009; 
Mlynsky and Bussi, 2017; Mailler et al., 2005). In order to circumvent the limitations imposed 
by these conventional assays, microbiologists have turned to graphene biosensing 




means to determine RNA-ligand binding events electrically (Forsyth et al., 2017). Currently, 
there is limited evidence that graphene devices can sense binding to relatively neutral, low 
molecular weight ligands. This work provides an interesting proof-of-concept that G-FETs are 
capable of detecting such interactions. Computer modeling aided in determining the extent of 
RNA structural changes after ligand addition. It was also used to predict suitable candidates for 
G-FET experiments.  
Finding a cheap labeling method suitable for scaling up G-FETs 
 
Manufacturers usually charge per base for production of amine-labeled RNA. Even 
though these aptamer domains are fairly small, ranging from around 60-120 bases, this can result 
in payment of over $1,000 for aptamer stocks. Since G-FET optimization requires large 
quantities of aptamer, direct purchase would not be sustainable for a long-term project. 
Conjugation of PBASE to synthetically transcribed aptamers provides a cheap method for 
functionalizing the G-FET.   
Ethylenediamine attachment has the potential to form an intermediate that prevents 
reaction with PBASE. Following formation of the Schiff Base, the remaining primary amine 
could lead to the formation of a cyclic diimine. If the remaining free amine of ethylenediamine 
attacks the 2’ aldehyde, the resulting cyclic diimine would prevent further addition of PBASE.  
However, this intermediate is not entropically favorable and thus should not greatly impact yield. 
Since AFM measurements confirmed a uniform distribution of RNA on the graphene surface 







AFM measurements and n-doping suggest unique interactions between RNA and graphene   
 Single stranded DNA (ssDNA) has been known to n-dope graphene (Wu et al., 2017). 
However, the extent of n-doping is largely determined by interactions of phosphate groups (p-
dopants) and aromatic nucleosides (n-dopants). Lin et al. have attributed observed n-doping in 1x 
PBS (Debye length = 0.7 nm) to the fact that the majority of the negatively charged phosphate 
groups were above the Debye length. Therefore, nucleoside adsorption seemed to be the major 
contributor, resulting in n-doping. This same study saw a positive Dirac shift when the 
complementary DNA strand was hybridized. They concluded that hybridization increased 
rigidity of the molecule, causing desorption of the nucleosides. After hybridization, extrinsic 
negative charge dominates, increasing hole carrier density (Lin et al., 2013).  
This reasoning can be applied to the observations made herein. As stated above, a left 
shift relative to bare graphene has also been observed in a recently published work on G-FET 
detection of the guanine riboswitch in 0.1x PBS (Tian et al., 2020). The measurements in this 
paper were also made in 0.1x PBS. This PBS concentration corresponds to ~2.4 nm Debye 
length. Since this aptamer has a theoretical height of 6.52 nm, a substantial portion of the 
negative sugar-phosphate backbone should be screened from the graphene surface. Also, AFM 
revealed a net aptamer height of about 5 nm, which is lower than the predicted 6.52 nm. This 
decrease in height suggests that a portion of the RNA had adsorbed onto the graphene surface. 
Therefore, n-doping nucleosides (and the pyrene groups) may have caused a left Dirac shift. 
Ligand addition is analogous to addition of a complementary DNA strand in that binding induces 
conformational changes and thus “rigidity”. This could desorb nitrogenous bases and cause p-
doping via extrinsic negative charge.  Although this model provides a simplified means to 




response to dry AFM. This may be the result of adsorption or increased compaction of the 
backbone when out of solution.  
G-FET measurements are promising for ligand detection 
 
 Results reveal that G-FETs can detect aptamer binding to small, uncharged molecules. 
This detection is highly specific for binding cognates, as demonstrated by changes in G-FET 
signal for hypoxanthine and not adenine. This signal change is likely due to structural changes in 
the RNA backbone because ligand alone could not induce a change in VD. A paper published 
after obtaining our results has confirmed many of our observations (Tian et al., 2020). Beyond an 
apparent negative shift after incubation with unlabeled Xpt, they reported positive shifts for a 
variety of ligands with known affinity to the aptamer (not including hypoxanthine). However, 
they did not include any negative controls to demonstrate ligand specificity.  
 By incubating Xpt with adenine and observing no shift, we provided a useful negative 
control to reinforce this specificity. We also provided evidence that a biologically relevant 
compound, hypoxanthine, causes Xpt conformational changes and subsequent G-FET signal 
changes.   
Molecular dynamics simulations are powerful complements to G-FET experiments 
 MD simulations for two crystal structures of Xpt (4FE5 and 1Y27) confirmed that Xpt 
compacts after ligand binding. Such compaction moves extrinsic charge closer to the graphene 
surface, resulting in change in G-FET signal. Since RMSD and Rg calculations are measured in 
units of Angstroms, net changes in position may be able to predict the actual magnitude of 
changes in Dirac voltage. It also shows promise in determining future candidates for G-FET 




aptamer showed no significant change in RMSD or Rg. Therefore, we predict that resulting G-
FET experiments will result in no signal change upon addition of the FMN ligand.  
Conclusion   
Short-Term Goals 
 
 This work has demonstrated the applicability of G-FET devices in sensing binding events 
between potential antibacterial targets (RNA aptamers) and their corresponding ligands. MD 
results also show great promise in the analysis and prediction of G-FET readouts. There are 
several future directions for this project that will aid in extending this device beyond well-
characterized aptamers.   
Further changes to the labeling protocol will be necessary to ensure sufficient quantities 
of PBASE-labeled RNA. For instance, it is important to maximize RNA concentrations because 
separation of excess PBASE requires running a second urea PAGE. Since extraction from gels 
typically results in ~ 50% yields (Pollard, 1998), and the labeling process likely results in added 
product loss, it will be necessary to begin with large quantities of pre-labeled RNA. For instance, 
it may be prudent to begin with multiple reductive aminations with ~ 1 nmol/reaction, combine 
products, and then link with 14 mM PBASE. Densitometry gel density must be further optimized 
to ensure efficient run time and maximizing the amount of labeled RNA loaded into the second 
Urea-PAGE.  
Also, characterization of the 3’-amine label and PBASE conjugate should be performed 
to complement AFM results. Mass spectrometry can be used to determine if a cyclic diimine 
intermediate is being formed prior to reduction with sodium cyanoborohydride. As stated 
previously, such a structure would prevent conjugation to the PBASE linker. Since the attack of 




intermediate, the resulting mass spectrum should show two peaks separated by approximately 18 
Daltons. This technique can also be used to determine addition of PBASE. Identification of the 
parent peak for unlabeled RNA can be predicted by base pair identity and chain length. Since 
PBASE addition is equivalent to a 385.41 Dalton mass increase from the parent peak, mass 
spectrometry is applicable for determining the presence or absence of PBASE conjugation.  
The model for graphene-RNA interactions provides a unique explanation for the 
observed n-doping effect of unbound RNA followed by p-doping with ligand addition. In order 
to provide further evidence for this phenomenon, hypoxanthine should be added to Xpt prior to 
plating on the graphene surface. Ligand binding should result in a compacted structure with 
extrinsic charge within the Debye length and limited desorption. A positive Dirac shift should be 
observed immediately, instead of the negative shift typically seen for unbound aptamer.  
G-FET results were confirmed by Tian et al. However, replicate studies must still be 
performed to confirm that our observed VD changes are statistically significant. Also, since 
guanine is known to bind Xpt with higher affinity than hypoxanthine (Batey et al., 2004), G-FET 
experiments with this ligand should be conducted. In order to augment evidence for the 
specificity of Xpt for its cognate ligands, it would be helpful to develop a mutant C74U Xpt 
aptamer via site-directed mutagenesis. As seen in our computational experiments, hypoxanthine 
and guanine should not bind this mutant, and thus no observable VD shift should result. Adenine, 
which resulted in no signal change in wildtype, should cause a readout for the mutant. Tian et al. 
also calculated binding dissociation constants, KD, by taking advantage of the relationship 
between ∆VD and ligand concentration. These findings were substantiated by MD prediction of 
the binding free energy, ∆G. Therefore, it would make sense to expand our MD simulations 




G-FET experiments call for experimental calculations of binding affinity, theoretical predictions 
based on MD would be a nice addition.  
Determining the detection limit of Xpt for guanine and hypoxanthine would demonstrate 
the utility of these devices for biomedical applications. The Burch lab had previously determined 
detection ranges for the CA1 aptamer to lie between 10 pg/mL-100 ng/mL (Kumar et al., 2020), 
well below physiological levels. The binding affinity of Xpt for hypoxanthine (KD = 3-4 μM) at 
physiological Mg2+ levels has also been determined (Batey et al., 2004). Further, transcription 
repression of Xpt has been shown to occur in purine concentrations of 1-10 μM. Determining 
detection limits for hypoxanthine and guanine that are below physiological levels would show 
the sensitivity of G-FETs as biosensors.   
G-FET experiments should also be performed with FMN to determine if the RMSD and 
Rg predictions are accurate.  If the G-FET shows limited or no signal change, RMSD and Rg 
measurements can be considered powerful predictive tools for this application. In order to avoid 
the use of multiple crystal structures, three-dimensional models of ligands can be created and 
docked into an existing crystal structure (Walker, 2015). For instance, inputs for guanine and/or 
adenine can be created using LEaP and can replace the complexed hypoxanthine. Docking of 
various ligands into the same system will eliminate the uncertainty in comparing trajectory 
results for separate crystal structures (i.e., 4FE5 vs. 1Y27). Also, this method is advantageous 
when there aren’t crystal structures available for multiple ligands complexed to the same 
aptamer. In addition, these simulations can be taken a step further to modify existing biological 






 It is the hope of the Boston College Meyer, Burch, and Van Opijnen labs that 
microfluidics can be used to parallelize G-FET sensing. It is their goal to create a single chip 
containing twenty graphene devices. These devices will be exposed and functionalized with the 
same aptamer target. Polydimethylsiloxane (PDMS) channels will be flow-controlled, allowing 
each device to be exposed to a different ligand. The result is a single chip that can screen 
multiple natural and therapeutic ligands for binding activity in a matter of hours. Not only will 
this allow for discovery of improved analogs to previously characterized aptamers, but it will 
also allow rapid screening of potential ligands for newly discovered aptamers. Such an 
innovation will provide a powerful tool for understanding biological binding events as well as for 
rapid discovery of antibiotics and antibiotic targets.  
 It can be also applied to antibiotic detection in environmental samples. Antibiotic 
pollution provides low concentrations of selective agents for antibiotic resistance. Detection of 
antibiotic pollution is critical for its removal from the environment (Mehlhorn et al., 2018). 
Production of synthetic aptamers that bind specific antibiotics can be first screened by the 
Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technique (Zhuo et al., 
2017). These aptamers can then be added to G-FET devices for subsequent detection of specific 
antibiotics in environmental samples. Therefore, it is critical that this device be developed for 










 Input files for structure prep, equilibration, and production of the 1Y27 apo and complex 
can be found in the supplementary materials. A MD trajectory movie of the 4FE5 aptamer can 
also be found on the online supplement.  
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